Company name JP Morgan Sec LLC
Headline Allergan plc 38.5b AMENDMENT


RNS Number : 1831M
J.P. Morgan Securities LLC
12 September 2019
 

Ap27

 

AMENDMENT

FORM 38.5(b)

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITHOUT RECOGNISED INTERMEDIARY STATUS, OR WITH RECOGNISED 
INTERMEDIARY STATUS BUT NOT DEALING IN A CLIENT-SERVING CAPACITY

 

 

1.          KEY INFORMATION

 

Name of exempt principal trader

J.P. Morgan Securities LLC

Company dealt in

Allergan plc

Class of relevant security to which the dealings being disclosed relate (Note 1)

$0.0001 ordinary shares

Date of dealing

9 September 2019

 

2.          INTERESTS AND SHORT POSITIONS

 

(a)         Interests and short positions (following dealing) in the class of relevant security dealt in (Note 2)

 

 

Long

Short

 

Number

 

(%)

Number

 

(%)

(1) Relevant securities

5,227,453 (1.59%)

969,917 (0.30%)

(2) Derivatives (other than options)

840,468 (0.26%)

4,391,725 (1.34%)

(3) Options and agreements to purchase/sell

1,350,139 (0.41%)

1,073,039 (0.33%)

Total

7,418,060 (2.26%)

6,434,682 (1.97%)

 

 

(b)         Interests and short positions in relevant securities of the company, other than the class dealt in (Note 2)

 

Class of relevant security:

Long

Short

 

Number

 

(%)

Number

 

(%)

(1) Relevant securities

-

-

(2) Derivatives (other than options)

-

-

(3) Options and agreements to purchase/sell

-

-

Total

-

-

 

 

 

Ap28

 

 

3.       DEALINGS (Note 3)

 

(a)      Purchases and sales

 

 

Purchases/ sales

 

Number of relevant securities

Price per unit  (USD)

Purchases

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sales

100

188

100

100

100

1,834

200

41

550

100

600

1,259

46

700

100

100

100

4,705

246

105,444

1,495

46

100

2,403

100

100

7,122

149

4,588

100

1,258

2,994

15,355

53,682

 

100

100

237

240

203

209

197

408

220

44

246

140

176

300

1,100

100

176

108

100

2

7,682

82,181

304

100

132

100

100

150

200

100

149

100

2,608

34

106

100

109

205

591

100

210

436

163

250

719

8,845

2,503

46

815

1,533

541

706

105,444

84

46

340

25

5,398

100

15,648

600

583

2,121

1,723

200

1,558

300

3,164

318

776

32,155

386

511

20,519

584

520

1,178

567

22,164

415

100

431

53,682

360

200

336

7,526

8,775

394

845

720

400

122

293

501

627

516

200

497

180

429

10

200

300

274

520

400

100

200

509

600

1,683

429

200

695

311

200

110

616

175

12

100

161.9100

162.0483

162.1700

162.2450

162.2750

162.3700

162.3950

162.4200

162.4400

162.4550

162.4650

162.4672

162.5300

162.5357

162.5400

162.5550

162.5600

162.5676

162.5811

162.5824

162.5899

162.6100

162.6300

162.6477

162.6500

162.6550

162.6568

162.6705

162.6733

162.6750

162.6786

162.6962

162.7000

162.7777

 

162.1500

162.1600

162.1700

162.1800

162.1900

162.1950

162.2000

162.2100

162.2300

162.2400

162.2450

162.2500

162.2700

162.2800

162.2827

162.2900

162.3100

162.3200

162.3300

162.3400

162.3533

162.3700

162.3800

162.3809

162.3900

162.4130

162.4200

162.4300

162.4321

162.4400

162.4452

162.4500

162.4577

162.4600

162.4700

162.4738

162.4800

162.4900

162.4982

162.5000

162.5100

162.5200

162.5300

162.5500

162.5563

162.5567

162.5568

162.5600

162.5688

162.5700

162.5715

162.5800

162.5824

162.6000

162.6100

162.6200

162.6250

162.6254

162.6300

162.6366

162.6400

162.6500

162.6562

162.6600

162.6650

162.6700

162.6750

162.6800

162.6850

162.6900

162.7000

162.7050

162.7100

162.7113

162.7200

162.7300

162.7400

162.7500

162.7567

162.7600

162.7650

162.7700

162.7777

162.7800

162.7850

162.7900

162.7945

162.7949

162.8000

162.8050

162.8100

162.8150

162.8200

162.8250

162.8300

162.8400

162.8500

162.8600

162.8634

162.8700

162.8950

162.9000

162.9050

162.9100

162.9150

162.9200

162.9250

162.9300

162.9350

162.9400

162.9450

162.9500

162.9550

162.9600

162.9750

162.9800

162.9850

162.9900

162.9950

163.0050

163.0100

163.1900

 

 

 

(b)      Derivatives transactions (other than options transactions)

 

Product name,

e.g. CFD

Nature of transaction

(Note 5)

Number of relevant securities

(Note 6)

Price per unit (USD)

(Note 4)

Equity Swaps

Long

76,000

105,444

53,682

162.4100

162.5824

162.7777

 

 

(c)      Options transactions in respect of existing relevant securities

 

 

(i)       Writing, selling, purchasing or varying

 

Product name,

e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price

(USD)

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 4)

(USD)

 

 

 

 

 

 

 

 

 

(ii)      Exercising

 

Product name,

e.g. call option

Number of securities

Exercise price per unit (Note 4) (USD)

 

 

 

 

 

 

(d)      Other dealings (including transactions in respect of new securities) (Note 3)

 

Nature of transaction

(Note 7)

Details

Price per unit

(if applicable) (Note 4)

 

 

 

 

 

 

 

 

 

 

Ap29

 

4.       OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

Full details of any agreement, arrangement or understanding between the person
disclosing and any other person relating to the voting rights of any relevant securities 
under any option referred to on this form or relating to the voting rights or future 
acquisition or disposal of any relevant securities to which any derivative referred to 
on this form is referenced. If none, this should be stated.

 

 

 

 

 

 

 

 

Is a Supplemental Form 38.5(b) attached? (Note 8)                    Yes

 

 

Date of disclosure

12 September 2019

Contact name

Alwyn Basch

Telephone number

020 7742 7407

Name of offeree/offeror with which connected

Allergan plc

Nature of connection (Note 9)

Financial Advisor to Allergan plc

 

Ap31

 

 

SUPPLEMENTAL FORM 38.5(b)

 

 

 

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DETAILS OF OPEN POSITIONS

 

(This form should be attached to Form 38.5(b)) OPEN POSITIONS (Note 1)

 

Product name,

e.g. call option

Written or purchased

Number of relevant securities to which the option or derivative relates

Exercise price (Note 2)

Type, e.g. American, European etc.

Expiry date

Call Option

Written

267,500

125.00

American

15/11/2019

Call Option

Purchased

214,500

150.00

American

15/11/2019

Call Option

Written

7,000

155.00

American

17/01/2020

Call Option

Written

5,000

210.00

American

17/01/2020

Call Option

Purchased

100,363

104.11

European

23/01/2020

Call Option

Written

100,363

104.11

European

23/01/2020

Call Option

Written

100,363

108.45

European

23/01/2020

Call Option

Purchased

100,363

108.45

European

23/01/2020

Put Option

Written

5,000

140.00

American

17/01/2020

Put Option

Written

65,100

95.00

American

17/01/2020

Put Option

Written

45,000

160.00

American

20/12/2019

Put Option

Written

300,000

150.00

American

19/06/2020

Put Option

Purchased

233,402

104.11

European

23/01/2020

Put Option

Written

233,402

104.11

European

23/01/2020

Put Option

Written

261,411

108.45

European

23/01/2020

Put Option

Purchased

261,411

108.45

European

23/01/2020

Put Option

Written

5,000

140.00

American

19/06/2020

Put Option

Purchasing

88,000

150.00

American

20/12/2019

Call Option

Purchasing

20,000

185.00

American

21/02/2020

Call Option

Written

10,000

170.00

American

21/02/2020

 

 

Notes

 

1.       Where there are open option positions or open derivative positions (except for CFDs), 
full details should be given. Full details of any existing agreements to purchase or to 
sell must also be given on this form.

 

2.       For all prices and other monetary amounts, the currency must be stated.

 

For full details of disclosure requirements, see Rules 8 and

38.5 of the Rules. If in doubt, consult the Panel.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
ISEELLFFKKFLBBE